HENRY SCHEIN INC reported fiscal year 2026 results: EPS $5.23 to $5.37 per diluted share. Guidance reaffirmed.
“Henry Schein today reaffirmed its financial guidance for 2026. Guidance is for current continuing operations and does not include the impact of restructuring expenses and related costs, amortization expense of acquired intangible assets, the impairment of intangible assets, changes in contingent consideration, costs associated with shareholder advisory matters, select implementation-related costs supporting value creation initiatives, and litigation settlements. This guidance also assumes that foreign currency exchange rates remain generally consistent with current levels. ● 2026 non-GAAP diluted EPS attributable to Henry Schein, Inc. is unchanged and expected to be $5.23 to $5.37.”
Earnings Releases
HENRY SCHEIN INC reported the first quarter ended March 28, 2026 results: revenue $3.4 billion, net income $107 million, EPS $0.92 per diluted share.
“First Quarter 2026 Financial Results ● Total net sales for the quarter were $3.4 billion, an increase of 6.3% compared to the first quarter of 2025 and reflects 2.5% internal sales growth, 0.7% sales growth from acquisitions, and a 3.1% increase resulting from foreign currency exchange. First quarter sales growth is detailed in Exhibit A 1. ● Global Distribution and Value-Added Services sales for the quarter increased 6.1%, and reflects 2.5% internal sales growth, 0.6% sales growth from acquisitions, and a 3.0% increase resulting from foreign currency exchange compared with the first quarter of 2025. The main components are: ● Global Dental Distribution merchandise sales for the quarter increased 9.0%, and by 3.0% internal sales growth, compared with the first quarter of 2025, with continuing strong momentum in the U.S. -2- more ● Global Dental Distribution equipment sales for the quarter increased 8.6%, and by 3.5% internal sales growth, compared with the first quarter of 2025. ● Glob”
Governance Changes
HENRY SCHEIN INC: Amended and restated By-Laws to eliminate requirement that Board appoint a President and to permit CEO who is not also President or Chairman (effective 2026-01-10).
“On January 10, 2026, upon the recommendation of the Nominating and Governance Committee of the Board, the Board approved an amendment and restatement of the Company’s Fourth Amended and Restated By-Laws (as amended and restated, the “By-Laws”), effective immediately.”
William K. "Dan" Daniel was appointed as Director at HENRY SCHEIN INC.
“On May 16, 2025, William K. “Dan” Daniel was appointed to the Company’s board of directors (the “ Board ”) as a director.”
Max Lin was appointed as Director at HENRY SCHEIN INC.
“On May 2, 2025, Max Lin was appointed to the Company’s board of directors (the “ Board ”) as a director.”
James P. Breslawski changed role as President at HENRY SCHEIN INC.
“On March 11, 2025, James P. Breslawski, President of Henry Schein, Inc. (the “Company”), informed the Company that effective as of April 1, 2025, he will transition out of the role of President of the Company.”
Robert J. Hombach was appointed as Director at HENRY SCHEIN INC.
“On January 27, 2025, Robert J. Hombach was appointed to the Board as a director.”
Earnings Releases
HENRY SCHEIN INC reported the first quarter ended March 30, 2024 results: revenue $3.2 billion, net income $93 million, EPS $0.72 per diluted share.
“incident and a strong pipeline of new specialty products and software innovation.” Mr. Bergman added. First-Quarter 2024 Financial Results ● Total net sales for the quarter were $3.2 billion, an increase of 3.7% compared with the first quarter of 2023. Internal sales decreased 1.8% 1 which includes: ● an approximate 300 to 400 basis points decrease in sales from the”
Earnings Releases
HENRY SCHEIN INC reported financial results for three months and full year ended December 30, 2023.
“On February 27, 2024, Henry Schein, Inc. issued a press release reporting the financial results for the three months and full year ended December 30, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.